...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Clinical Study on Prospective Efficacy of All-Trans Acid, Realgar-Indigo Naturalis Formula Combined with Chemotherapy as Maintenance Treatment of Acute Promyelocytic Leukemia
【24h】

Clinical Study on Prospective Efficacy of All-Trans Acid, Realgar-Indigo Naturalis Formula Combined with Chemotherapy as Maintenance Treatment of Acute Promyelocytic Leukemia

机译:全反酸,雄黄-靛蓝自然配方配合化学疗法维持急性早幼粒细胞白血病的前瞻性疗效研究

获取原文
           

摘要

Objectives. To test the efficiency and safety of sequential application of retinoic acid (ATRA), Realgar-Indigo naturalis formula (RIF) and chemotherapy (CT) were used as the maintenance treatment in patients with acute promyelocytic leukemia (APL).Methods. This was a retrospective study of 98 patients with newly diagnosed APL who accepted two different maintenance treatments. After remission induction and consolidation chemotherapy according to their Sanz scores, patients received two different kinds of maintenance scheme. The first regimen was using ATRA, RIF, and standard dose of CT sequentially (ATRA/RIF/CT regimen), while the second one was using ATRA and low dose of chemotherapy with methotrexate (MTX) plus 6-mercaptopurine (6-MP) alternately (ATRA/CTlowregimen). The OS, DFS, relapse rate, minimal residual disease, and adverse reactions in two groups were monitored and evaluated.Results. ATRA/RIF/CT regimen could effectively reduce the chance of relapse in different risk stratification of patients, but there was no significant difference in 5-year DFS rate and OS rate between the two groups. Besides, the patients in the experimental group suffered less severe adverse reactions than those in the control group.Conclusions. The repeated sequential therapeutic regimen to APL with ATRA, RIF, and chemotherapy is worth popularizing for its high effectiveness and low toxicity.
机译:目标。为了检验视黄酸(ATRA)顺序应用的有效性和安全性,采用Realgar-Indigo naturalis配方(RIF)和化学疗法(CT)作为急性早幼粒细胞白血病(APL)患者的维持治疗。这是一项对98名新诊断为APL的患者的回顾性研究,他们接受了两种不同的维持治疗。在根据Sanz评分进行缓解诱导和巩固化疗后,患者接受了两种不同的维持方案。第一个方案是依次使用ATRA,RIF和标准剂量的CT(ATRA / RIF / CT方案),第二个方案是使用ATRA和低剂量的甲氨蝶呤(MTX)加6-巯基嘌呤(6-MP)化疗交替(ATRA / CTlowregimen)。监测和评估两组的OS,DFS,复发率,最小残留病和不良反应。 ATRA / RIF / CT方案可有效减少患者不同风险分层中复发的机会,但两组的5年DFS率和OS率之间无显着差异。此外,实验组患者的不良反应较对照组少。 ATRA,RIF和化学疗法对APL的重复顺序治疗方案因其高效和低毒而值得推广。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号